Improvement of peptide vectors for gene delivery with active targeting profiles for phosphatidylserine

Journal of Peptide Science

Volumn 15, Issue 2, 2009, Pages 114-119

  Kuriyama, Shinichi ^a   Taguchi, Yasushi ^a   Nishimura, Kanako ^a   Yanagibashi, Kazutoshi ^a   Katayama, Yoshiki ^b   Niidoime, Takuro ^b,c  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

helix peptide; Gene delivery; Phosphatidylserine; Targeting; Transfection

Indexed keywords

AMINO ACID; LIPOSOME; PEPTIDE; PHOSPHATIDYLSERINE; PLASMID DNA;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RAT; TARGET CELL; TUMOR CELL; ANIMAL; CERCOPITHECUS; CHEMISTRY; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM; MOLECULAR GENETICS; SYNTHESIS; TUMOR CELL LINE; VERO CELL;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PHOSPHATIDYLSERINES; VERO CELLS;

EID: 61449229352     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1104     Document Type: Article

References (34)

1. Conwell CC, Huang L. Recent advances in non-viral gene delivery. Adv. Genet. 2005; 53: 1-18.
2. Wagner E. Advances in cancergene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and dsRNA nucleic acids. J. BUON 2007; 12: S77-S82.
3. Kawakami S, Higuchi Y, Hashida M. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J. Pharm. Sci. 2008; 97: 726-745.
4. Romano G. Current development of nonviral-mediated gene transfer. Drug News Perspect. 2007; 20: 227-731.
5. Gao X, Kim KS, Liu D. Nonviral gene delivery: what we know and what is next. AAPS J. 2007; 9: E92-104.
6. Ishikawa A, Zhou YM, Kambe N, Nakayama Y. Enhancement of star vector-based gene delivery to endothelial cells by addition of RGD-peptide. Bioconjugate Chem. 2008; 19: 558-561.
7. Parkhouse SM, Garnett MC, Chan WC. Targeting of polyamidoamine- DNA nanoparticles using the Staudinger ligation: attachment of an RGD motif either before or after complexation. Bioorg. Med. Chem. 2008; 16: 6641-6650.
8. Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J. 2007; 9: E18-E29.
9. Furuhata M, Danev R, Nagayama K, Yamada Y, Kawakami H, Toma K, Hattori Y, Maitani Y. Decaarginine-PEG-artificial lipid/DNA complex forgenedelivery: nanostructure and transfection efficiency. J. Nanosci. Nanotechnol. 2008; 8: 2308-2815.
10. Fujita T, Furuhata M, Hattori Y, Kawakami H, Toma K, Maitani Y. High genedelivery intumorby intratumoral injection of tetraarginine-PEG lipid-coated protamine/DNA. J. Control. Release 2008; 129: 124-127.
11. Khalil IA, Kogure K, Futaki S, Harashima H. Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. Int. J. Pharm. 2008; 354: 39-48.
12. Suk JS, Suh J, Choy K, Lai SK, Fu J, Hanes J. Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles. Biomaterials 2006; 27: 5143-5150.
13. Lo SL, Wang S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 2008; 29: 2408-2414.
14. Duvshani-Eshet M, Keren H, Oz S, Radzishevsky IS, Mor A, Machluf M. Effect of peptides bearing nuclear localization signals on therapeutic ultrasound mediated gene delivery. J. Gene. Med. 2008; 10: 1150-1159.
15. McKenzie DL, Kwok KY, Rice KG. A potent new class of reductively activated peptide gene delivery agents. J. Biol. Chem. 2000; 275: 9970-9977.
16. Stevenson M, Ramos-Perez V, Singh S, Soliman M, Preece JA, Briggs SS, Read ML, Seymour LW. Delivery of siRNA mediated by histidine containing reducible polycations. J. Control. Release 2008; 130: 46-56.
17. Parker AL, Eckley L, Singh S, Preece JA, Collins L, Fabre JW. (LYS)16- based reducible polycations provide stable polyplexes with anionic fusogenic peptides and efficient gene delivery to post mitotic cells. Biochim. Biophys. Acta 2007; 1770: 1331-1137.
18. Oishi J, Kawamura K, Kang JH, Kodama K, Sonoda T, Murata M, Niidome T, Katayama Y. An intracellular kinase signal-responsive gene carrier for disordered cell-specific gene therapy. J. Control. Release 2006; 110: 431-436.
19. Kuriyama S, Taguchi Y, Nishimura K, Mizuguchi K, Kobayashi K, Katayama Y, Yanagibashi K, Niidome T. Peptide vector for gene delivery with high affinity for phosphatidylserine. J. Pept. Sci. 2006; 12: 626-632.
20. Gilbert GE, Furie BC, Furie B. Binding of human factor VIII to phospholipid vesicles. J. Biol. Chem. 1990; 265: 815-822.
21. Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry 1993; 32: 9577-9585.
22. Takeshima K, Smith C, Tait J, Fujikawa K. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb. Haemostasis 2003; 89: 788-794.
23. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Syntheticfactor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Blood 1990; 75: 1999-2004.
24. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler IJ. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991; 51: 3062-3066.
25. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002; 62: 6132-6140.
26. Pohl A, Lage H, Muller P, Pomorski T, Herrmann A. Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem. J. 2002; 365: 259-268.
27. Woehlecke H, Pohl A, Baerens NA, Lage H, Herrmann A. Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overex pressing the half-size ABC transporter BCRP (ABCG2). Biochem. J. 2003; 376: 489-495.
28. Martin S, Pombo I, Poncet P, David B, ArockM, Blank U. Immunologic stimulation of mast cells leads to the reversible exposure of phosphatidylserine in the absence of apoptosis. Int. Arch. Allergy Immunol. 2000; 123: 249-258.
29. Dillon SR, Constantinescu A, Schlissel MS. Annexin V binds to positively selected B cells. J. Immunol. 2001; 16: 58-71.
30. Demo SD, Masuda E, Rossi AB, Throndset BT, Gerard AL, Chan EH, Armstrong RJ, Fox BP, Lorens JB, Payan DG, Scheller RH, Fisher JM. Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay. Cytometry 1999; 36: 340-348.
31. Niidome T, Ohmori N, Ichinose A, Wada A, Mihara H, Hirayama T, Aoyagi H. Binding of cationic a-helical peptides to plasmid DNA and their gene transfer abilities into cells. J. Biol. Chem. 1997; 272: 15307-15312.
32. Ohmori N, Niidome T, Kiyota T, Lee S, Sugihara G, Wada A, Hirayama T, Aoyagi H. Importance of hydrophobic region in amphiphilic structures of α-helical peptides for their gene transfer-ability into cells. Biochem. Biophys. Res. Commun. 1998; 245: 259-265.
33. Niidome T, Urakawa M, Takaji K, Matsuo Y, Ohmori N, Wada A, Hirayama T, Aoyagi H. Influence of lipophilic groups in cationic a-helical peptides on their abilities to bind with DNA and deliver gene into cells. J. Pept. Res. 1999; 54: 361-367.
34. Zachowski A. Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement. Biochem. J. 1993; 294: 1-14.